These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 8713690)

  • 1. Monoamine oxidase inhibitors. An update on drug interactions.
    Livingston MG; Livingston HM
    Drug Saf; 1996 Apr; 14(4):219-27. PubMed ID: 8713690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine oxidase inhibitors. A perspective on their use in the elderly.
    Volz HP; Gleiter CH
    Drugs Aging; 1998 Nov; 13(5):341-55. PubMed ID: 9829163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current place of monoamine oxidase inhibitors in the treatment of depression.
    Shulman KI; Herrmann N; Walker SE
    CNS Drugs; 2013 Oct; 27(10):789-97. PubMed ID: 23934742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
    Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R
    Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transdermal delivery system of monoamine oxidase inhibitors.
    VanDenBerg CM
    J Clin Psychiatry; 2012; 73 Suppl 1():25-30. PubMed ID: 22951239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of monoamine oxidase and its inhibitors.
    Jarrott B; Vajda FJ
    Med J Aust; 1987 Jun; 146(12):634-8. PubMed ID: 3114597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoamine oxidase inhibitors and pressor response to dietary amines].
    Tipton KF
    Vopr Med Khim; 1997; 43(6):494-503. PubMed ID: 9503566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAOIs to RIMAs in anaesthesia--a literature review.
    Hill S; Yau K; Whitwam J
    Psychopharmacology (Berl); 1992; 106 Suppl():S43-5. PubMed ID: 1546140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
    Flockhart DA
    J Clin Psychiatry; 2012; 73 Suppl 1():17-24. PubMed ID: 22951238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
    Patkar AA; Pae CU; Masand PS
    CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions with reversible monoamine oxidase-A inhibitors.
    Callingham BA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S42-50. PubMed ID: 8313396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
    Lotufo-Neto F; Trivedi M; Thase ME
    Neuropsychopharmacology; 1999 Mar; 20(3):226-47. PubMed ID: 10063483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoamine oxidase inhibitors: a new generation.
    Robinson DS
    Psychopharmacol Bull; 2002; 36(3):124-38. PubMed ID: 12473970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.